Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria

Archives of Internal Medicine

Volumn 157, Issue 16, 1997, Pages 1857-1862

  Stevens, David A ^a,b,c,e   Lee, Jeannette Y ^a,c,d  

^a CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYCLOSPORIN; ITRACONAZOLE; PHENYTOIN; PYRROLE DERIVATIVE; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NERVOUS SYSTEM INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; SINUSITIS; TREATMENT OUTCOME;

EID: 0030866456     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.16.1857     Document Type: Article

References (13)

1. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis. 1990;12:1147-1201.
2. Tucker RM, Haq Y, Denning DW, et al. The toxicity of itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother. 1990;26:561-566.
3. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37:310-344.
4. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989;86:791-800.
5. Viviani MA, Tortorano AM, Woestenborghs R, Cauwenbergh G. Experience with itraconazole in deep mycoses in northern Italy. Mykosen. 1987;30:233-244.
6. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol. 1990;23:607-614.
7. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994; 97:135-144.
8. Dismukes WE, Bennett JE, Drutz DJ, et al. Criteria for evaluating therapeutic response to antifungal drugs. Rev Infect Dis. 1980;2:535-544.
9. Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B. Blood. 1995;86(suppl 1):849A. Abstract.
10. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses. 1993;36:421-424.
11. Denning DW, Tucker RM, Hostetler JS, et al. Oral itraconazole therapy of cryptococcal meningitis and cryptococcosis in patients with AIDS. In: Vanden Bossche H, Mackenzie DWR, Cauwenbergh G, et al, eds. Mycoses in AIDS Patients. New York, NY: Plenum Publishing Corp; 1990:305-324.
12. Tucker RM, Hanson LH, Denning DW, et al. The interaction of azoles with rifampin, phenytoin and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14:165-174.
13. Kramer MR, Marshall SE, Denning DW, et al. Drug interaction between cyclosporin and itraconazole in heart and heart-lung and lung transplant recipients with fungal disease. Ann Intern Med. 1990;113:327-329.